REGN
Regeneron·NASDAQ
--
--(--)
--
--(--)
REGN fundamentals
Regeneron (REGN) released its earnings on Jan 30, 2026: revenue was 3.88B (YoY +2.51%), beat estimates; EPS was 11.44 (YoY -5.22%), beat estimates.
Revenue / YoY
3.88B
+2.51%
EPS / YoY
11.44
-5.22%
Report date
Jan 30, 2026
REGN Earnings Call Summary for Q4,2025
- Revenue Growth: Q4 2025 revenue $3.9B (+3% YoY), driven by DUPIXENT (+32%), LIBTAYO (+13%), and EYLEA HD (+66%).
- Pipeline Momentum: 4+ FDA approvals anticipated in 2026, including EYLEA HD prefilled syringe and LIBTAYO adjuvant CSCC. 18 Phase III trials to enroll ~35,000 patients.
- Financial Strength: $4.1B free cash flow; $3.8B returned to shareholders via buybacks and dividends.
- Strategic Differentiation: Long-acting IL-13/IL-4 antibodies, cemdisiran for geographic atrophy, and GLP-1/GIP/PCSK9 combo offer best-in-class profiles.
- Patient Access: $200M patient affordability program; U.S. drug cost negotiations nearing resolution.
EPS
Actual | 6.6 | 7.16 | 8.36 | 9.53 | 9.89 | 25.8 | 15.37 | 23.72 | 11.49 | 9.77 | 11.14 | 12.56 | 10.09 | 10.24 | 11.59 | 11.86 | 9.55 | 11.56 | 12.46 | 12.07 | 8.22 | 12.89 | 11.83 | 11.44 | ||||||||||||||||
Forecast | 6.0637 | 5.913 | 6.9531 | 8.3793 | 8.6849 | 17.7219 | 10.3451 | 20.4022 | 9.7249 | 8.6183 | 9.7577 | 10.2473 | 9.5198 | 9.8471 | 10.6819 | 10.7308 | 10.171 | 10.6177 | 11.695 | 11.2822 | 8.6217 | 8.4309 | 9.6545 | 10.7356 | ||||||||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +8.84% | +21.09% | +20.23% | +13.73% | +13.88% | +45.58% | +48.57% | +16.26% | +18.15% | +13.36% | +14.17% | +22.57% | +5.99% | +3.99% | +8.50% | +10.52% | -6.11% | +8.87% | +6.54% | +6.98% | -4.66% | +52.89% | +22.53% | +6.56% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.83B | 1.95B | 2.29B | 2.42B | 2.53B | 5.14B | 3.45B | 4.95B | 2.97B | 2.86B | 2.94B | 3.41B | 3.16B | 3.16B | 3.36B | 3.43B | 3.15B | 3.55B | 3.72B | 3.79B | 3.03B | 3.68B | 3.75B | 3.88B |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.76B | 1.73B | 2.08B | 2.42B | 2.50B | 3.96B | 2.75B | 4.56B | 2.69B | 2.79B | 2.92B | 3.12B | 3.00B | 3.02B | 3.23B | 3.29B | 3.23B | 3.38B | 3.67B | 3.74B | 3.25B | 3.29B | 3.59B | 3.81B |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +4.03% | +13.10% | +10.19% | +0.22% | +0.97% | +29.67% | +25.73% | +8.54% | +10.22% | +2.24% | +0.71% | +9.26% | +5.42% | +4.47% | +4.04% | +4.25% | -2.49% | +4.83% | +1.25% | +1.25% | -6.74% | +11.78% | +4.51% | +1.93% |
Earnings Call
You can ask Aime
What were the key takeaways from Regeneron's earnings call?What is the revenue and EPS growth rate for Regeneron year over year?What were the key takeaways from Regeneron’s earnings call?What guidance did Regeneron's management provide for the next earnings period?Did Regeneron beat or miss consensus estimates last quarter?What does Regeneron do and what are its main business segments?What is Regeneron's gross profit margin?What is the market's earnings forecast for Regeneron next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
